2020

Commentary: Workshop on normal reference ranges for estradiol in postmenopausal women: commentary from The North American Menopause Society on low-dose vaginal estrogen therapy labeling

The Society continues to request FDA to enact modifications in the estrogen therapy black box warning for low-dose vaginal estrogen formulations dosed within the postmenopausal estradiol reference ranges. Such modifications would include removal of the black box warning and replacement with cautions regarding the need for medical evaluation if postmenopausal bleeding or spotting occurs and for women to engage their oncologists in decision-making if they have a prior estrogen-sensitive cancer. 

2019

Symposium Report: Workshop on normal reference ranges for estradiol in postmenopausal women, September 2019, Chicago, Illinois

The aim of this workshop was to review existing analytical methodologies for measuring estradiol in postmenopausal women and to assess existing data and study cohorts of postmenopausal women for their suitability to establish normal postmenopause ranges. The anticipated outcome was to develop recommendations for establishing normal ranges generated with a standardized and certified assay that could be adopted by clinical and research communities.  

Utian Translational Science Symposium: new therapies for leiomyomas: when surgery may not be the best option

This workshop discusses therapeutic approaches to uterine leiomyomas when surgery is not the optimal choice. Uterine leiomyomas arise from a single clonal cell and are the most common gynecologic disorder affecting reproductive and perimenopausal women worldwide. The prevalence of this disorder is approximately 40% to 70% in White women and 60% to 80% in Black women.  

2018

Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health

The consensus recommendations will assist healthcare professionals in managing genitourinary syndrome of menopause (GSM), with a goal of improving the care and quality of life for women with or at high risk of breast cancer. These women deserve high-quality, comprehensive care, including evidence-based management of GSM.  

Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations

The Menopause Society and the Women and Mood Disorders Task Force of the National Network of Depression Centers collaborated to convene an 11-member expert panel to systematically review the scientific literature on depressive disorders and depressive symptoms in perimenopausal and postmenopausal women to develop clinical guidelines for the evaluation and treatment of perimenopausal depression.